
Small Is Beautiful
Encouraged by government stimulus programs, banks are finding new ways to finance SMEs. Once the economy recovers, will the surge of interest recede?
As economies grapple with the economic disaster of the novel coronavirus, the value and number of M&A deals worldwide have deflated.
Biotech delivered some welcome news to a faltering mergers and acquisitions market last month when it was the focus of two multibillion-dollar deals: Johnson & Johnson’s purchase of biotech developer Momenta Pharmaceuticals for $6.5 billion in cash, and Sanofi’s $3.4 billion agreement to buy San Francisco–based Principia Biopharma. New Jersey–based J&J said the Momenta deal provides an opportunity for its Janssen Pharmaceutical subsidiary to broaden its leadership in treating immune-mediated diseases. Sanofi, which has a large budget for acquisitions, is on the hunt for more biotechs.
The two takeovers were a bright spot in a traditionally slow month for a global M&A market that was already running at a seven-year low. As economies grapple with the economic disaster of the novel coronavirus, the value and number of M&A deals worldwide have deflated.
“Some opportunistic deals are still occurring, but it will take a bit more time for confidence levels to return to the boardroom as deal makers assess post-Covid business models and valuations,” says Matt Toole, director of deals intelligence at Refinitiv.
Yet, capital markets activity is keeping investment bankers busy in the absence of big M&A deals. Corporate bond markets shattered all-time records and equity capital-raising volumes surged in the second quarter, Toole says.
IPO bankers skipped vacation this year, says William K. Smith, CEO and co-founder of Renaissance Capital. Capital raised from new listings set a record for the month of August. And while the J&J and Sanofi deals were a rare bright spot for M&A, they reflected a hot market in their own industry; four health care IPOs came to market in a single week last month, averaging a 39.9% return from their offer price. “With those numbers, we expect the biotech boom to continue in the fall,” Smith says.
The race for a vaccine and treatment for the coronavirus has spurred interest in the biotech sector. German-based coronavirus vaccine developer CureVac, backed by Bill Gates, soared 249% in its Nasdaq debut on August 20, the largest first-day gain for a US IPO in 15 years.